Why clinical trials fail to validate efficacy of interventions predicted by observational studies of ‘risks’ for dementia-Alzheimer syndrome?, Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis, and Cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology
Prof John Breitner is Professor of Psychiatry at McGill University. He is also Director of the Centre for Studies on Prevention of Alzheimer’s Disease at the Douglas Research Centre
